Share Price and Basic Stock Data
Last Updated: December 19, 2025, 8:35 pm
| PEG Ratio | -4.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
GlaxoSmithKline Pharmaceuticals Ltd (GSK) operates in the highly competitive pharmaceutical sector in India, characterized by a diverse product portfolio that spans prescription medications, vaccines, and consumer healthcare products. As of the latest reporting, the company recorded ₹3,740 Cr in revenue from operations, demonstrating a consistent growth trajectory, especially when compared to ₹3,278 Cr in the previous year. The quarterly sales figures also reflect this upward trend, with the most recent quarter ending September 2023 showing sales of ₹957 Cr. This is a notable increase from ₹762 Cr in the same period last year, indicating robust demand for its offerings. However, it’s important to note that GSK’s sales have experienced some fluctuations, with a peak of ₹1,011 Cr projected for September 2024, suggesting potential seasonality or market dynamics at play. Overall, the revenue growth seems promising, but investors should remain vigilant about market competition and consumer preferences that can impact future sales.
Profitability and Efficiency Metrics
GSK’s profitability metrics are impressive, particularly its operating profit margin (OPM), which stood at 31%. This points to a healthy operational efficiency, allowing the company to maintain a solid profit even amid rising costs. The net profit for the latest reported period was ₹950 Cr, translating to an earnings per share (EPS) of ₹54.52, which reflects strong profitability relative to its share price. The company has also maintained a high return on equity (ROE) of 46.9%, showcasing effective use of shareholder capital to generate profits. However, while these figures are commendable, the price-to-earnings (P/E) ratio of 45.2 could indicate that the stock is somewhat overvalued relative to its earnings, which may raise concerns for potential investors about future growth justifying this valuation. Additionally, the interest coverage ratio of 1007.30x illustrates GSK’s robust ability to cover interest expenses, suggesting a strong operational base to weather financial uncertainties.
Balance Sheet Strength and Financial Ratios
GSK’s balance sheet appears solid, with total assets reported at ₹4,108 Cr against minimal borrowings of just ₹36 Cr. This low debt level provides the company with significant financial flexibility and reduces risk exposure during economic downturns. The reserves also stood at ₹1,782 Cr, supporting a strong equity base that enhances the company’s financial stability. However, the price-to-book value (P/BV) ratio of 24.98x raises a flag regarding valuation; it suggests that the stock is trading at a premium relative to its book value, which could deter value-seeking investors. Furthermore, the cash conversion cycle of -31 days indicates excellent efficiency in managing working capital, allowing GSK to quickly turn sales into cash. This efficiency is complemented by a current ratio of 1.79, which suggests that the company can comfortably meet its short-term liabilities. Overall, while the balance sheet is robust, the valuation metrics warrant caution.
Shareholding Pattern and Investor Confidence
The shareholding pattern of GSK shows a strong foundation of promoter confidence, with promoters holding 75% of the equity. This level of ownership can be reassuring for retail investors, as it often indicates alignment of interests between the management and shareholders. Foreign institutional investors (FIIs) have gradually increased their stake from 2.28% in December 2022 to 4.79% by September 2025, reflecting growing confidence among international investors in GSK’s long-term prospects. On the other hand, domestic institutional investors (DIIs) have seen a slight decline from 10.29% to 7.75% over the same period, which could suggest caution from local institutions. The total number of shareholders has also increased to 1,22,904, indicating a rising interest from the retail segment. This mixed pattern of institutional investment could suggest a divergence in sentiment, where some investors see potential, while others may be taking a more conservative approach.
Outlook, Risks, and Final Insight
Looking ahead, GSK appears well-positioned in the pharmaceutical space, bolstered by strong financial health and a solid operational framework. However, the high valuation metrics pose a risk, particularly if future earnings do not meet investor expectations. Market competition remains a significant risk, as new entrants and generic products can erode market share and profitability. Additionally, regulatory changes in the pharmaceutical landscape could pose challenges. Investors should keep a close watch on quarterly performance to gauge whether the current growth trajectory can be sustained. While the fundamentals suggest a stable outlook, the premium valuation requires careful consideration. In essence, GSK represents a compelling investment opportunity, but potential investors must weigh the risks against the strong operational performance and financial robustness the company has demonstrated.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 151 Cr. | 120 | 235/84.3 | 33.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.63 Cr | 1,151.80 | 52.58 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Glaxosmithkline Pharmaceuticals Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 745 | 917 | 802 | 787 | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 |
| Expenses | 596 | 660 | 574 | 618 | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 |
| Operating Profit | 149 | 257 | 229 | 170 | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 |
| OPM % | 20% | 28% | 29% | 22% | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% |
| Other Income | 31 | 22 | 12 | 38 | 54 | 28 | -135 | 32 | 36 | 39 | 35 | 41 | 44 |
| Interest | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 16 | 16 | 16 | 17 | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 |
| Profit before tax | 163 | 262 | 224 | 190 | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 |
| Tax % | 27% | 26% | 27% | 30% | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% |
| Net Profit | 119 | 193 | 165 | 133 | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 |
| EPS in Rs | 7.04 | 11.42 | 9.71 | 7.88 | 7.81 | 12.84 | 2.70 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 |
Last Updated: August 1, 2025, 9:00 pm
Below is a detailed analysis of the quarterly data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 805.00 Cr.. The value appears to be declining and may need further review. It has decreased from 974.00 Cr. (Mar 2025) to 805.00 Cr., marking a decrease of 169.00 Cr..
- For Expenses, as of Jun 2025, the value is 554.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 641.00 Cr. (Mar 2025) to 554.00 Cr., marking a decrease of 87.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 251.00 Cr.. The value appears to be declining and may need further review. It has decreased from 333.00 Cr. (Mar 2025) to 251.00 Cr., marking a decrease of 82.00 Cr..
- For OPM %, as of Jun 2025, the value is 31.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Mar 2025) to 31.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2025) to 44.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 16.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 279.00 Cr.. The value appears to be declining and may need further review. It has decreased from 359.00 Cr. (Mar 2025) to 279.00 Cr., marking a decrease of 80.00 Cr..
- For Tax %, as of Jun 2025, the value is 27.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 27.00%.
- For Net Profit, as of Jun 2025, the value is 205.00 Cr.. The value appears to be declining and may need further review. It has decreased from 263.00 Cr. (Mar 2025) to 205.00 Cr., marking a decrease of 58.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 12.10. The value appears to be declining and may need further review. It has decreased from 15.52 (Mar 2025) to 12.10, marking a decrease of 3.42.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:20 am
| Metric | Dec 2013 | Mar 2015n n 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,563 | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,709 |
| Expenses | 2,034 | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,497 |
| Operating Profit | 528 | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,212 |
| OPM % | 21% | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 33% |
| Other Income | 203 | 149 | 125 | 119 | 70 | 131 | -262 | 9 | 1,401 | 103 | -21 | 149 | 156 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 2 |
| Depreciation | 20 | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 |
| Profit before tax | 711 | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,300 |
| Tax % | 32% | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | 26% | |
| Net Profit | 482 | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 955 |
| EPS in Rs | 28.43 | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 56.39 |
| Dividend Payout % | 88% | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% | 99% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -10.37% | 4.15% | 26.78% | -79.10% | 284.95% | 373.46% | -63.95% | -3.44% | 57.29% |
| Change in YoY Net Profit Growth (%) | 0.00% | 14.53% | 22.63% | -105.88% | 364.05% | 88.52% | -437.42% | 60.52% | 60.73% |
Glaxosmithkline Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 3% |
| 3 Years: | 5% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 35% |
| 3 Years: | -20% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 13% |
| 3 Years: | 26% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 45% |
| 3 Years: | 36% |
| Last Year: | 47% |
Last Updated: September 5, 2025, 4:50 am
Balance Sheet
Last Updated: December 10, 2025, 2:42 am
| Month | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,905 | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 1,538 |
| Borrowings | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 36 |
| Other Liabilities | 1,136 | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,312 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 1,922 |
| Total Liabilities | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,133 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 3,665 |
| Fixed Assets | 100 | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 291 |
| CWIP | 62 | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 17 |
| Investments | 10 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,313 |
| Other Assets | 2,958 | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,255 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,044 |
| Total Assets | 3,130 | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,133 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 3,665 |
Below is a detailed analysis of the balance sheet data for Glaxosmithkline Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 169.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 169.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,538.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,782.00 Cr. (Mar 2025) to 1,538.00 Cr., marking a decrease of 244.00 Cr..
- For Borrowings, as of Sep 2025, the value is 36.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 10.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 26.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,922.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,147.00 Cr. (Mar 2025) to 1,922.00 Cr., marking a decrease of 225.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,665.00 Cr.. The value appears to be improving (decreasing). It has decreased from 4,108.00 Cr. (Mar 2025) to 3,665.00 Cr., marking a decrease of 443.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 291.00 Cr.. The value appears strong and on an upward trend. It has increased from 284.00 Cr. (Mar 2025) to 291.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 14.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 3.00 Cr..
- For Investments, as of Sep 2025, the value is 1,313.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,118.00 Cr. (Mar 2025) to 1,313.00 Cr., marking an increase of 195.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,044.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,692.00 Cr. (Mar 2025) to 2,044.00 Cr., marking a decrease of 648.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,665.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,108.00 Cr. (Mar 2025) to 3,665.00 Cr., marking a decrease of 443.00 Cr..
Notably, the Reserves (1,538.00 Cr.) exceed the Borrowings (36.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2013 | Mar 2015n n 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 524.00 | 633.00 | 476.00 | 418.00 | 507.00 | 600.00 | 657.00 | 563.00 | 742.00 | 788.00 | 890.00 | -9.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 14 | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 |
| Inventory Days | 109 | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 |
| Days Payable | 90 | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 |
| Cash Conversion Cycle | 33 | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | -4 | -31 |
| Working Capital Days | -45 | -48 | 26 | 7 | -90 | -72 | -38 | -39 | -94 | -57 | -64 | -99 |
| ROCE % | 34% | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Midcap Fund | 1,200,000 | 1.32 | 308.34 | N/A | N/A | N/A |
| Kotak Large & Midcap Fund | 1,100,000 | 0.94 | 282.65 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 913,226 | 2.77 | 234.65 | 853,907 | 2025-12-08 01:23:05 | 6.95% |
| Nippon India Growth Mid Cap Fund | 559,000 | 0.34 | 143.64 | N/A | N/A | N/A |
| Kotak Flexicap Fund | 399,331 | 0.18 | 102.61 | N/A | N/A | N/A |
| Aditya Birla Sun Life ELSS Tax Saver Fund | 333,621 | 0.55 | 85.72 | 532,312 | 2025-12-15 01:10:59 | -37.33% |
| Aditya Birla Sun Life MNC Fund | 260,835 | 1.85 | 67.02 | N/A | N/A | N/A |
| Bandhan ELSS Tax Saver Fund | 230,000 | 0.81 | 59.1 | 220,000 | 2025-12-15 01:10:59 | 4.55% |
| Aditya Birla Sun Life Multi-Cap Fund | 227,787 | 0.86 | 58.53 | N/A | N/A | N/A |
| Mahindra Manulife Small Cap Fund | 182,918 | 1.11 | 47 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 54.52 | 41.14 | 36.08 | 99.29 | 31.35 |
| Diluted EPS (Rs.) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 |
| Cash EPS (Rs.) | 58.70 | 38.94 | 39.93 | 104.06 | 25.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 115.19 | 104.93 | 102.79 | 157.19 | 87.26 |
| Revenue From Operations / Share (Rs.) | 221.32 | 203.87 | 191.95 | 193.50 | 172.70 |
| PBDIT / Share (Rs.) | 78.11 | 60.88 | 53.42 | 49.45 | 41.84 |
| PBIT / Share (Rs.) | 74.17 | 56.76 | 49.54 | 45.42 | 37.20 |
| PBT / Share (Rs.) | 74.37 | 48.18 | 49.37 | 45.99 | 26.80 |
| Net Profit / Share (Rs.) | 54.76 | 34.83 | 36.05 | 100.04 | 21.14 |
| NP After MI And SOA / Share (Rs.) | 54.91 | 35.07 | 36.41 | 100.04 | 21.14 |
| PBDIT Margin (%) | 35.29 | 29.86 | 27.82 | 25.55 | 24.22 |
| PBIT Margin (%) | 33.51 | 27.84 | 25.80 | 23.47 | 21.53 |
| PBT Margin (%) | 33.60 | 23.63 | 25.72 | 23.76 | 15.51 |
| Net Profit Margin (%) | 24.74 | 17.08 | 18.78 | 51.69 | 12.24 |
| NP After MI And SOA Margin (%) | 24.81 | 17.20 | 18.96 | 51.69 | 12.24 |
| Return on Networth / Equity (%) | 47.67 | 33.42 | 35.41 | 63.64 | 24.22 |
| Return on Capital Employeed (%) | 57.03 | 47.33 | 41.95 | 26.21 | 35.80 |
| Return On Assets (%) | 22.64 | 16.70 | 18.53 | 36.57 | 11.49 |
| Asset Turnover Ratio (%) | 0.97 | 1.00 | 0.80 | 0.83 | 0.93 |
| Current Ratio (X) | 1.79 | 1.84 | 1.88 | 2.18 | 1.63 |
| Quick Ratio (X) | 1.54 | 1.49 | 1.53 | 1.87 | 1.22 |
| Inventory Turnover Ratio (X) | 7.45 | 1.11 | 0.81 | 1.04 | 0.89 |
| Dividend Payout Ratio (NP) (%) | 80.12 | 91.24 | 247.21 | 29.98 | 189.20 |
| Dividend Payout Ratio (CP) (%) | 74.76 | 81.66 | 223.39 | 28.82 | 155.15 |
| Earning Retention Ratio (%) | 19.88 | 8.76 | -147.21 | 70.02 | -89.20 |
| Cash Earning Retention Ratio (%) | 25.24 | 18.34 | -123.39 | 71.18 | -55.15 |
| Interest Coverage Ratio (X) | 1007.30 | 573.35 | 499.36 | 419.65 | 200.69 |
| Interest Coverage Ratio (Post Tax) (X) | 703.51 | 408.84 | 336.84 | 185.96 | 131.22 |
| Enterprise Value (Cr.) | 47339.67 | 31854.06 | 21275.97 | 25686.86 | 23243.30 |
| EV / Net Operating Revenue (X) | 12.63 | 9.22 | 6.54 | 7.84 | 7.94 |
| EV / EBITDA (X) | 35.77 | 30.89 | 23.51 | 30.67 | 32.80 |
| MarketCap / Net Operating Revenue (X) | 13.00 | 9.53 | 6.90 | 8.59 | 8.34 |
| Retention Ratios (%) | 19.87 | 8.75 | -147.21 | 70.01 | -89.20 |
| Price / BV (X) | 24.98 | 18.52 | 12.88 | 10.58 | 16.51 |
| Price / Net Operating Revenue (X) | 13.00 | 9.53 | 6.90 | 8.59 | 8.34 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.06 | 0.01 |
After reviewing the key financial ratios for Glaxosmithkline Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 54.52. This value is within the healthy range. It has increased from 41.14 (Mar 24) to 54.52, marking an increase of 13.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 54.76. This value is within the healthy range. It has increased from 34.83 (Mar 24) to 54.76, marking an increase of 19.93.
- For Cash EPS (Rs.), as of Mar 25, the value is 58.70. This value is within the healthy range. It has increased from 38.94 (Mar 24) to 58.70, marking an increase of 19.76.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 115.19. It has increased from 104.93 (Mar 24) to 115.19, marking an increase of 10.26.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 115.19. It has increased from 104.93 (Mar 24) to 115.19, marking an increase of 10.26.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 221.32. It has increased from 203.87 (Mar 24) to 221.32, marking an increase of 17.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 78.11. This value is within the healthy range. It has increased from 60.88 (Mar 24) to 78.11, marking an increase of 17.23.
- For PBIT / Share (Rs.), as of Mar 25, the value is 74.17. This value is within the healthy range. It has increased from 56.76 (Mar 24) to 74.17, marking an increase of 17.41.
- For PBT / Share (Rs.), as of Mar 25, the value is 74.37. This value is within the healthy range. It has increased from 48.18 (Mar 24) to 74.37, marking an increase of 26.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 54.76. This value is within the healthy range. It has increased from 34.83 (Mar 24) to 54.76, marking an increase of 19.93.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 54.91. This value is within the healthy range. It has increased from 35.07 (Mar 24) to 54.91, marking an increase of 19.84.
- For PBDIT Margin (%), as of Mar 25, the value is 35.29. This value is within the healthy range. It has increased from 29.86 (Mar 24) to 35.29, marking an increase of 5.43.
- For PBIT Margin (%), as of Mar 25, the value is 33.51. This value exceeds the healthy maximum of 20. It has increased from 27.84 (Mar 24) to 33.51, marking an increase of 5.67.
- For PBT Margin (%), as of Mar 25, the value is 33.60. This value is within the healthy range. It has increased from 23.63 (Mar 24) to 33.60, marking an increase of 9.97.
- For Net Profit Margin (%), as of Mar 25, the value is 24.74. This value exceeds the healthy maximum of 10. It has increased from 17.08 (Mar 24) to 24.74, marking an increase of 7.66.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 24.81. This value exceeds the healthy maximum of 20. It has increased from 17.20 (Mar 24) to 24.81, marking an increase of 7.61.
- For Return on Networth / Equity (%), as of Mar 25, the value is 47.67. This value is within the healthy range. It has increased from 33.42 (Mar 24) to 47.67, marking an increase of 14.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 57.03. This value is within the healthy range. It has increased from 47.33 (Mar 24) to 57.03, marking an increase of 9.70.
- For Return On Assets (%), as of Mar 25, the value is 22.64. This value is within the healthy range. It has increased from 16.70 (Mar 24) to 22.64, marking an increase of 5.94.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.97. It has decreased from 1.00 (Mar 24) to 0.97, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.79. This value is within the healthy range. It has decreased from 1.84 (Mar 24) to 1.79, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.54. This value is within the healthy range. It has increased from 1.49 (Mar 24) to 1.54, marking an increase of 0.05.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.45. This value is within the healthy range. It has increased from 1.11 (Mar 24) to 7.45, marking an increase of 6.34.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 80.12. This value exceeds the healthy maximum of 50. It has decreased from 91.24 (Mar 24) to 80.12, marking a decrease of 11.12.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 74.76. This value exceeds the healthy maximum of 50. It has decreased from 81.66 (Mar 24) to 74.76, marking a decrease of 6.90.
- For Earning Retention Ratio (%), as of Mar 25, the value is 19.88. This value is below the healthy minimum of 40. It has increased from 8.76 (Mar 24) to 19.88, marking an increase of 11.12.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 25.24. This value is below the healthy minimum of 40. It has increased from 18.34 (Mar 24) to 25.24, marking an increase of 6.90.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,007.30. This value is within the healthy range. It has increased from 573.35 (Mar 24) to 1,007.30, marking an increase of 433.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 703.51. This value is within the healthy range. It has increased from 408.84 (Mar 24) to 703.51, marking an increase of 294.67.
- For Enterprise Value (Cr.), as of Mar 25, the value is 47,339.67. It has increased from 31,854.06 (Mar 24) to 47,339.67, marking an increase of 15,485.61.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 12.63. This value exceeds the healthy maximum of 3. It has increased from 9.22 (Mar 24) to 12.63, marking an increase of 3.41.
- For EV / EBITDA (X), as of Mar 25, the value is 35.77. This value exceeds the healthy maximum of 15. It has increased from 30.89 (Mar 24) to 35.77, marking an increase of 4.88.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 3. It has increased from 9.53 (Mar 24) to 13.00, marking an increase of 3.47.
- For Retention Ratios (%), as of Mar 25, the value is 19.87. This value is below the healthy minimum of 30. It has increased from 8.75 (Mar 24) to 19.87, marking an increase of 11.12.
- For Price / BV (X), as of Mar 25, the value is 24.98. This value exceeds the healthy maximum of 3. It has increased from 18.52 (Mar 24) to 24.98, marking an increase of 6.46.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.00. This value exceeds the healthy maximum of 3. It has increased from 9.53 (Mar 24) to 13.00, marking an increase of 3.47.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Glaxosmithkline Pharmaceuticals Ltd:
- Net Profit Margin: 24.74%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 57.03% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 47.67% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 703.51
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.54
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 45 (Industry average Stock P/E: 43.25)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 24.74%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | GSK House, Dr. Annie Besant Road, Mumbai Maharashtra 400030 | in.investorquery@gsk.com http://www.gsk-india.com |
| Management | |
|---|---|
| Name | Position Held |
| Ms. R S Karnad | Chairperson |
| Mr. B Akshikar | Managing Director |
| Mr. J Chandy | WholeTime Director & CFO |
| Mr. S Williams | Non Executive Director |
| Mr. M Anand | Independent Director |
| Mr. P R Somasundaram | Independent Director |
| Dr. A Wadhawan | Independent Director |
| Dr.(Ms.) S Maheshwari | Independent Director |
FAQ
What is the intrinsic value of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's intrinsic value (as of 19 December 2025) is 1733.59 which is 31.45% lower the current market price of 2,529.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 42,874 Cr. market cap, FY2025-2026 high/low of 3,516/1,921, reserves of ₹1,538 Cr, and liabilities of 3,665 Cr.
What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?
The Market Cap of Glaxosmithkline Pharmaceuticals Ltd is 42,874 Cr..
What is the current Stock Price of Glaxosmithkline Pharmaceuticals Ltd as on 19 December 2025?
The current stock price of Glaxosmithkline Pharmaceuticals Ltd as on 19 December 2025 is 2,529.
What is the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Glaxosmithkline Pharmaceuticals Ltd stocks is 3,516/1,921.
What is the Stock P/E of Glaxosmithkline Pharmaceuticals Ltd?
The Stock P/E of Glaxosmithkline Pharmaceuticals Ltd is 45.0.
What is the Book Value of Glaxosmithkline Pharmaceuticals Ltd?
The Book Value of Glaxosmithkline Pharmaceuticals Ltd is 101.
What is the Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd?
The Dividend Yield of Glaxosmithkline Pharmaceuticals Ltd is 1.66 %.
What is the ROCE of Glaxosmithkline Pharmaceuticals Ltd?
The ROCE of Glaxosmithkline Pharmaceuticals Ltd is 63.2 %.
What is the ROE of Glaxosmithkline Pharmaceuticals Ltd?
The ROE of Glaxosmithkline Pharmaceuticals Ltd is 46.9 %.
What is the Face Value of Glaxosmithkline Pharmaceuticals Ltd?
The Face Value of Glaxosmithkline Pharmaceuticals Ltd is 10.0.